Q1 FY27 saw 19.1% revenue growth, 28.6% EBITDA growth, and strong patient volume gains, driven by favorable test/geographic mix and CGHS/ECHS price hikes. Expansion continued in rural India and internationally, with new acquisitions and digital initiatives supporting future growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.